

References

Chapter 30

- 1 International Agency for Research on Cancer. Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Available from: http://globocan.iarc.fr/Pages/factsheets_population.aspx (last accessed 18 November 2015).
- 2 Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. *European Journal of Cancer*. 2013;**49**(6):1374–403.
- 3 Eurostat AD. Causes of Death – Standardised Death Rate (per 100 000 Inhabitants) 2013. Available from: http://epp.eurostat.ec.europa.eu/portal/page/portal/product_details/publication?p_product_code=KS-30-08-357 (last accessed 18 November 2015).
- 4 Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. First-line Herceptin monotherapy in metastatic breast cancer use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *Oncology*. 2001;**61**(Suppl. 2):37–42.
- 5 Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. *Lancet*. 2005;**365**(9472):1687–717.
- 6 Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *New England Journal of Medicine*. 2010;**363**(8):711–23.
- 7 Animal Cell Technology Industrial Platform. Monoclonal Antibodies Approved by the EMA and FDA for Therapeutic Use (Status 2013). Available from: <http://www.actip.org/products/monoclonal-antibodies-approved-by-the-ema-and-fda-for-therapeutic-use/> (last accessed 18 November 2015).
- 8 European Medicines Agency. Orphan Drug Designations 2015. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2009/11/human_orphan_000468.jsp&mid=WC0b01ac058001d12b (last accessed 18 November 2015).
- 9 SMS-Oncology. EMA Anticancer Drug Approval in 2014. Available from: <http://sms-oncology.com/blog/ema-anticancer-drug-approval-in-2014/> (last accessed 18 November 2015).
- 10 Niraula S, Seruga B, Ocana A, Shao T, Goldstein R, Tannock IF, et al. The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. *Journal of Clinical Oncology*. 2012;**30**(24):3012–19.
- 11 National Cancer Institute. Targeted Cancer Therapies. Available from: <http://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet> (last accessed 18 November 2015).
- 12 European Medicines Agency. Orphan Designation 2014. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000029.jsp& (last accessed 18 November 2015).
- 13 Food and Drug Administration. Developing Products for Rare Diseases & Conditions. Available from: <http://www.fda.gov/forindustry/DevelopingProductsforRareDiseasesConditions/default.htm> (last accessed 18 November 2015).
- 14 Amir E, Seruga B, Kwong R, Tannock IF, Ocana A. Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer? *European Journal of Cancer*. 2012;**48**(3):385–8.

- 15 Shea MB, Roberts SA, Walrath JC, Allen JD, Sigal EV. Use of multiple endpoints and approval paths depicts a decade of FDA oncology drug approvals. *Clinical Cancer Research*. 2013;**19**(14):3722–31.
- 16 StatBite: Drugs in development by therapeutic area (2010). *Journal of the National Cancer Institute*. 2012;**104**(2):86.
- 17 Wilking N, Jönsson B, Högberg D, Justo N. Comparator Report on Patient Access to Cancer Drugs in Europe. Available from: http://www.interpharma.ch/sites/default/files/medikamente_zugang_zu_innovation_comparator_report_2009_0.pdf (last accessed 18 November 2015).
- 18 European Medicines Agency. EudraGMDP database. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/eudra_gmp_database.jsp&mid=WC0b01ac058006e06e (last accessed 18 November 2015).
- 19 Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. *Lancet Oncology*. 2013;**14**(12):1165–74.
- 20 Marsland T, Robbins G, Marks A, Cassell R, Philips DG, King K. Reducing cancer costs and improving quality through collaboration with payers: a proposal from the Florida society of clinical oncology. *Journal of Oncology Practice*. 2010;**6**(5):265–9.
- 21 Jonsson B, Wilking N. A global comparison regarding patient access to cancer drugs. *Annals of Oncology*. 2007;**18**(Suppl. 3):iii1–iii77.
- 22 Light DW, Kantarjian H. Market spiral pricing of cancer drugs. *Cancer*. 2013;**119**(22):3900–2.
- 23 Martell RE, Sermer D, Getz K, Kaitin KI. Oncology drug development and approval of systemic anti-cancer therapy by the US Food and Drug Administration. *Oncologist*. 2013;**18**(1):104–11.
- 24 Siddiqui M, Rajkumar SV. The high cost of cancer drugs and what we can do about it. *Mayo Clinic Proceedings*. 2012;**87**(10):935–43.
- 25 Amir E, Seruga B, Martinez-Lopez J, Kwong R, Pandiella A, Tannock IF, et al. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. *Journal of Clinical Oncology*. 2011;**29**(18):2543–9.
- 26 Khayat D. Innovative cancer therapies – putting costs into context. *Cancer*. 2012;**118**(9):2367–71.
- 27 Jönsson B, Wilking, N. LIF Rapport: Läkemedelsutvecklingen inom cancerområdet. 2008:6. Rapport från LIF till Utredningen om en nationell cancerstrategi. Available from: <http://www.forskasverige.se/wp-content/uploads/Lakemedelsutvecklingen-Inom-Cancerområdet-LIF.pdf> (last accessed 18 November 2015).
- 28 Bergstrom R. Drivers of the cost of cancer care. *Lancet Oncology*. 2012;**13**(1):14–15.
- 29 Olver I. Challenges of accessing cancer medicines in Australia. *Lancet Oncology*. 2013;**14**(11):1040–2.
- 30 Generics and Biosimilars Initiative. Pricing of Biosimilars. Available from: <http://gabionline.net/Biosimilars/Research/Pricing-of-biosimilars> (last accessed 18 November 2015).
- 31 Gascon P, Tesch H, Verpoort K, Rosati MS, Salesi N, Agrawal S, et al. Clinical experience with Zanzio® in Europe: what have we learned? *Supportive Care in Cancer*. 2013;**21**(10):2925–32.
- 32 PM-Live. Roche blocks Herceptin biosimilar in India. Available from: http://www.pmlive.com/pharma_news/roche_blocks_herceptin_biosimilar_in_india_542104 (last accessed 18 November 2015).
- 33 Jönsson B, Wilking N. New cancer drugs in Sweden: assessment, implementation and access. *Journal of Cancer Policy*. 2014;**2**:45–62.
- 34 Helsana. Medikamentenstatistik 2013: Onkologie. Available from: <https://www.helsana.ch/docs/medikamentenstatistik-onkologie.pdf> (last accessed 18 November 2015).
- 35 Civan A, Koksall, B. The effect of newer drugs on health spending: do they really increase the costs? *Health Economics*. 2010;**19**(5):581–95.
- 36 Hirsch BR, Califf RM, Cheng SK, Tasneem A, Horton J, Chiswell K, et al. Characteristics of oncology clinical trials: insights from a systematic analysis of ClinicalTrials.gov. *Journal of the American Medical Association Internal Medicine*. 2013;**173**(11):972–9.
- 37 Parkinson B, Pearson SA, Viney R. Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique. *European Journal of Health Economics*. 2014;**15**(1):93–112.
- 38 Adamski J, Godman B, Ofierska-Sujkowska G, Osińska B, Herholz H, Wendykowska K., et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. *BMC Health Service Response*. 2010;**10**:153.
- 39 Cheema PK, Gavura S, Migus M, Godman B, Yeung L, Trudeau ME. International variability in the reimbursement of cancer drugs by pub-

- lically funded drug programs. *Current Oncology*. 2012;**19**(3):165–76.
- 40 Espin J, Rovira J, Garcia L. Experiences and Impact of European Risk-Sharing Schemes Focusing on Oncology Medicines. Available from: http://www.researchgate.net/publication/260343816_Experiences_and_Impact_of_European_Risk-Sharing_Schemes_Focusing_on_Oncology_Medicines (last accessed 18 November 2015).
 - 41 Williamson S. Patient access schemes for high-cost cancer medicines. *Lancet Oncology*. 2010;**11**(2): 111–12.
 - 42 Vitry AI, Thai LP, Lu CY. Time and geographical variations in utilization of endocrine therapy for breast cancer in Australia. *Internal Medicine Journal*. 2011;**41**(2):162–6.
 - 43 Chang CS, Yang YH, Hsu CN, Lin MT. Trends in the treatment changes and medication persistence of chronic myeloid leukemia in Taiwan from 1997 to 2007: a longitudinal population database analysis. *BMC Health Service Research*. 2012;**12**:359.
 - 44 Wang Z, Askamit I, Tuscher L, Bergstrom K. Rates of guideline adherence among US community oncologists treating NSCLC. *American Journal of Managed Care*. 2013;**19**(3):185–92.
 - 45 Wilking N, Jönsson B, Högberg D, Justo N. *Comparator Report on Patient Access to Cancer Drugs in Europe*. Stockholm, Karolinska Institutet and Stockholm School of Economics, 2009.
 - 46 Richards MA. Extent and Causes of International Variations in Drug Usage. Available from: <https://www.gov.uk/government/publications/extent-and-causes-of-international-variations-in-drug-usage> (last accessed 18 November 2015).
 - 47 Opticon. Skillnader i användning av innovativa läkemedel: en internationell jämförande studie på uppdrag av LIF. Available from: <http://www.lif.se/globalassets/pdf/rapporter-externa/skillnader-i-anvandning-av-innovativa-lakemedel.pdf.pdf> (last accessed 18 November 2015).
 - 48 Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. *CA: A Cancer Journal for Clinicians*. 2009;**59**(1):56–66.
 - 49 Nekhlyudov L, Li L, Ross-Degnan D, Wagner AK. Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer. *Breast Cancer Research and Treatment*. 2011;**130**(2):681–9.
 - 50 van Herk-Sukel MP, van de Poll-Franse LV, Voogd AC, Nieuwenhuijzen GA, Coebergh JW, Herings RM. Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. *Breast Cancer Research and Treatment*. 2010;**122**(3):843–51.
 - 51 Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. *Journal of Clinical Oncology*. 2014;**32**(4):306–11.
 - 52 Zafar SY, Peppercorn JM, Schrag D, Taylor DH, Goetzinger AM, Zhong X, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. *Oncologist*. 2013;**18**(4):381–90.
 - 53 Peter A, Ubel P. Doctor, first tell me what it costs. *New York Times*. 3 November 2013. Available from: http://www.nytimes.com/2013/11/04/opinion/doctor-first-tell-me-what-it-costs.html?_r=3& (last accessed 18 November 2015).
 - 54 Ramsey S, Blough D, Kirchhoff A, Kreizenbeck K, Fedorenko C, Snell K, et al. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. *Health Affairs*. 2013;**32**(6):1143–52.
 - 55 Lu CY, Srasuebkul P, Drew AK, Chen K, Ward RL, Pearson SA. Trastuzumab therapy in Australia: which patients with HER2+ metastatic breast cancer are assessed for cardiac function? *Breast*. 2013;**22**(4):482–7.
 - 56 Wettermark B, Zoega H, Furu K, Korhonen M, Hallas J, Norgaard M, et al. The Nordic prescription databases as a resource for pharmacoepidemiological research – a literature review. *Pharmacoepidemiology & Drug Safety*. 2013;**22**(7):691–9.
 - 57 van Herk-Sukel M, Lemmens V, van de Poll-Franse L, Herings R, Coebergh J. Record linkage for pharmacoepidemiological studies in cancer patients. *Pharmacoepidemiology & Drug Safety*. 2012;**21**:94–103.
 - 58 Soon SS, Lim HY, Lopes G, Ahn J, Hu M, Ibrahim HM, et al. Roles of cancer registries in enhancing oncology drug access in the Asia-Pacific region. *Asian Pacific Journal of Cancer Prevention*. 2013;**14**(4):2159–65.
 - 59 Lee SJ, Earle CC, Weeks JC. Outcomes research in oncology: history, conceptual framework, and

- trends in the literature. *Journal of the National Cancer Institute*. 2000;**92**(3):195–204.
- 60** Franken MG, Gaultney JG, Blommestein HM, Huijgens PC, Sonneveld P, Redekop WK, et al. Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib? *Value in Health*. 2014;**17**(2):245–53.
- 61** ASCO. CancerLinQ. Building a Transformation in Cancer Care. Available from: <http://www.asco.org/quality-guidelines/cancerlinq> (last accessed 18 November 2015).
- 62** National Cancer Intelligence Network. National Cancer Data Repository. Available from: http://www.ncin.org.uk/collecting_and_using_data/national_cancer_data_repository/ (last accessed 18 November 2015).
- 63** Khayat D. Innovative cancer therapies: putting costs into context. *Cancer*. 2012;**118**(9):2367–71.
- 64** Wilking N, Jönsson B. A Pan-European Comparison Regarding Patient Access to Cancer Drugs. Available from: http://www.med.mcgill.ca/epidemiology/courses/EPIB654/Summer2010/Policy/Cancer_Report%20Karolinska.pdf (last accessed 18 November 2015).
- 65** Hofmarcher T, Jönsson B, Wilking N. Access to High-Quality Oncology Care across Europe. Available from: <http://www.ihe.se/access-to-high-quality.aspx> (last accessed 18 November 2015).
- 66** International Society for Pharmacoeconomics and Outcomes Research. France – Pharmaceuticals. Available from: <http://www.ispor.org/htaroadmaps/france.asp> (last accessed 18 November 2015).
- 67** Wilking U, Jonsson B, Wilking N, Bergh J. Trastuzumab use in breast cancer patients in the six Health Care Regions in Sweden. *Acta Oncologica*. 2010;**49**(6):844–50.
- 68** Pearson SA, Ringland CL, Ward RL. Trastuzumab and metastatic breast cancer: trastuzumab use in Australia – monitoring the effect of an expensive medicine access program. *Journal of Clinical Oncology*. 2007;**25**(24):3688–93.